In the REDEFINE 1 phase 3a trial, semaglutide at a dose of 2.4 mg with cagrilintide at a dose of 2.4 mg led to significant body weight reduction in adults without diabetes and Let me introduce you to a NEW peptide : Cagrilintide is an amylin analog which is now being developed in combination with GLP 1 agonist Semaglutide to achieve sustained Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 ScienceDirect